Reduction in Intrasubject Variability in the Pharmacokinetic Response to Insulin After Subcutaneous Co-Administration with Recombinant Human Hyaluronidase in Healthy Volunteers

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes Technology & Therapeutics

• Publication date

  2011-09-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1089/dia.2011.0115PMID 21714645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update of Type 1 Diabetes

  2013cited by this paper
• Absorption kinetics of insulin after subcutaneous administration.

  2009cited by this paper
• Accelerated Pharmacokinetics and Glucodynamics of Prandial Insulins Injected With Recombinant Human Hyaluronidase

  2009influential reference
• Prevention of Hypoglycemia While Achieving Good Glycemic Control in Type 1 Diabetes

  2008cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine

  2008cited by this paper
• Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

  2007cited by this paper
• Update in type 1 diabetes.

  2007cited by this paper
• Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine

  2007cited by this paper
• Meal Simulation Model of the Glucose-Insulin System

  2007cited by this paper
• A recombinant human enzyme for enhanced interstitial transport of therapeutics.

  2006cited by this paper
• Subcutaneous insulin: pharmacokinetic variability and glycemic variability.

  2005influential reference
• The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges

  2004cited by this paper
• Measurement of Insulin Absorption and Insulin Action

  2004cited by this paper
• Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.

  2003cited by this paper
• Using new insulin strategies in the outpatient treatment of diabetes: clinical applications.

  2003cited by this paper
• Skin-related complications of insulin therapy: epidemiology and emerging management strategies.

  2003cited by this paper
• Insulin analogues and other developments in insulin therapy for diabetes

  2003cited by this paper
• Variability of Insulin Absorption and Insulin Action

  2002cited by this paper
• Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.

  1999cited by this paper
• Insulin Lispro in CSII: Results of a Double-Blind Crossover Study

  1997cited by this paper
• [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin

  1994cited by this paper
• Monomeric insulins obtained by protein engineering and their medical implications

  1988cited by this paper
• Effect of hyaluronidase on the subcutaneous absorption of electrolytes in humans.

  1950cited by this paper
• Identity of Hyaluronidase and Spreading Factor

  1940cited by this paper

• Accelerated absorption of regular insulin administered via a vascularizing permeable microchamber implanted subcutaneously in diabetic Rattus norvegicus

  2022cites this paper
• Subcutaneous Delivery of High-Dose/Volume Biologics: Current Status and Prospect for Future Advancements

  2021cites this paper
• Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery

  2021cites this paper
• DDDT_A_287323 159..170

  2021cites this paper
• Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge.

  2020cites this paper
• Recombinant human hyaluronidase PH20-mediated dermal spreading activity in mice is not altered by steroids, antihistamines, or salicylic acid

  2020cites this paper
• Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

  2020cites this paper
• Pharmacokinetic and Pharmacodynamic Assessment of Novel and Biosimilar Insulins

  2019cites this paper
• ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20

  2019influential citation
• Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects

  2018cites this paper
• Subcutaneous Insulin Administration: Sufficient Progress or Ongoing Need?

  2018cites this paper
• [Fast-acting insulin - new developments towards more flexibility for the patient].

  2016cites this paper
• Future Drug Treatments for Type 1 Diabetes

  2016cites this paper
• Kurzwirksame Insuline — Neuentwicklungen hin zu mehr Flexibilität für den Patienten

  2016cites this paper
• Moving toward the ideal insulin for insulin pumps

  2016cites this paper
• MESA 1: NUEVOS MEDICAMENTOS EN DIABETES MELLITUS TIPO 1

  2015cites this paper
• Methods for Quantifying Insulin Sensitivity and Determining Insulin Time-Action Profiles

  2015influential citation
• New insulins for diabetes

  2015cites this paper
• Les insulines, ultra-rapides, et techniques pour accélérer l’action des insulines rapides

  2014cites this paper
• New developments in insulin therapy for type 2 diabetes.

  2014cites this paper
• Closer to ideal insulin action: ultra fast acting insulins.

  2013cites this paper
• Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase

  2013cites this paper
• Pharmacokinetics and Postprandial Glycemic Excursions following Insulin Lispro Delivered by Intradermal Microneedle or Subcutaneous Infusion

  2012cites this paper
• Ultrafast-Acting Insulins: State of the Art

  2012cites this paper
• Accelerating and Improving the Consistency of Rapid-Acting Analog Insulin Absorption and Action for Both Subcutaneous Injection and Continuous Subcutaneous Infusion Using Recombinant Human Hyaluronidase

  2012cites this paper
• Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device

  2012cites this paper
• New developments to optimize postprandial glucose control with insulin in patients with diabetes

  2012cites this paper
• Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion.

  2011cites this paper
• Late-Breaking Clinical Trial Report

  2011cites this paper